SMS Pharma's Q1FY27 revenue grew 6% YoY to ₹207 Cr, with PAT up 8% YoY to ₹20 Cr.

EBITDA margin remained strong at 20%. Growth was broad-based across high-value APIs, led by Anti-diabetic (33% of revenue) and European markets (34%). The company is strategically investing in R&D, expanding its team to 200 for niche APIs and peptides, and targeting 2x R&D investment.

Key initiatives include backward integration for margin improvement and a ramp-up of high-volume products, aiming for global leadership in Anti-inflammatory APIs.

Recent highlights include 4 DMF/CEP filings in Q1FY27 and board approval for a ₹50 Cr loan to its peptide subsidiary for R&D. The ₹280 Cr capex program for capacity expansion and new API pipelines is on track for FY27 completion, expected to deliver high-teen returns.

Management aims for revenue growth and margin expansion, targeting 10 DMF/CEP filings for FY27.